clinicalstudy

Clovis Oncology: Phase 3 Study of Rubraca

Clovis Oncology: Phase 3 Study of Rubraca

Clovis Oncology, Inc. (NASDAQ: CLVS) reported the first set of data from the Phase 3 ARIEL4 study of Rebraca will take place in an oral presentation today at the Society of Gynecologic Oncology Virtual Annual Meeting on Woman’s Cancer.  T..